IkT-148009 is under clinical development by Inhibikase Therapeutics and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IkT-148009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ikt-148009 is under development for the treatment of Parkinson’s disease. The drug candidate is administered orally. It acts by targeting Abelson tyrosine kinase (BCR-ABL) enzyme and ABL1 (c-Abl). It is developed based on RAMP technology.
It was also under development for the treatment of dysphagia, neurogenic constipation and multiple system atrophy.
Inhibikase Therapeutics overview
Inhibikase Therapeutics is a biotechnology business dedicated to the development and commercialization of small-molecule kinase inhibitor therapeutics for the safe and effective treatment of neurological illnesses both inside and outside the brain. The company is headquartered in Atlanta, Georgia, the US.
For a complete picture of IkT-148009’s drug-specific PTSR and LoA scores, buy the report here.